annual meeting program - American Society of Clinical Oncology

9:45 AM - 11:15 AM
CLINICAL SCIENCE SYMPOSIUM
Promising Targeted Therapies for Head and Neck Cancer
Location: E354a
CME credit: 1.5
Track(s): Head and Neck Cancer
Monday, June 7, 2010
Bonnie S. Glisson, MD—Chair
University of Texas M. D. Anderson Cancer Center
9:45 AM Phase II study of figitumumab in patients with recurrent and/or metastatic
squamous cell carcinoma of the head and neck: GORTEC 2008–02. (Abstract
#5500)
S. Schmitz, M. Kaminsky-Forrett, S. Henry, S. Zanetta, L. Geoffrois, E. Bompas,
A. Moxhon, J. Guigay, J. H. Machiels
Discussion
10:00 AM Bonnie S. Glisson, MD (Abstract #5500)
University of Texas M. D. Anderson Cancer Center
10:15 AM BIBW 2992 versus cetuximab in patients with metastatic or recurrent head
and neck cancer (SCCHN) after failure of platinum-containing therapy with a
cross-over period for progressing patients: Preliminary results of a
randomized, open-label phase II study. (Abstract #5501)
T. Y. Seiwert, P. M. Clement, D. Cupissol, J. Del Campo, H. de Mont-Serrat,
H. C. Thurm, A. S. Blackman, E. E. Cohen
Discussion
10:30 AM Lisa F. Licitra, MD (Abstract #5501)
Istituto Nazionale Tumori
10:45 AM Long-term results in a cohort of medullary thyroid cancer (MTC) patients
(pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET,
VEGFR2, and RET. (Abstract #5502)
R. Kurzrock, E. E. Cohen, S. I. Sherman, D. G. Pfister, R. B. Cohen, D. Ball,
D. S. Hong, C. S. Ng, R. Salgia, M. J. Ratain
Discussion
11:00 AM Manisha H. Shah, MD (Abstract #5502)
The Ohio State University
353
MONDAY